Drug Profile
Ciltacabtagene autoleucel - Janssen Biotech/Nanjing Legend Biotech
Alternative Names: BCMA CAR-T - Janssen Biotech; BCMA CAR-T cell therapy- Janssen Biotech/Nanjing Legend Biotech; CAR-T cell therapy - Nanjing; CARVYKTI; cilta-cel; JNJ 4528; JNJ-68284528; LCAR-B38M; LCAR-B38M CAR-T cell therapy; LCARB38M/JNJ-4528Latest Information Update: 25 Apr 2024
Price :
$50
*
At a glance
- Originator Legend Biotech USA; Nanjing Legend Biotech
- Developer Janssen Biotech; Legend Biotech USA; Nanjing Legend Biotech
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Multiple myeloma
- Phase II Smoldering multiple myeloma
Most Recent Events
- 22 Apr 2024 European Commission approves conversion of for conditional marketing authorization application to standard marketing authorization application for treatment of Multiple myeloma
- 22 Apr 2024 European Commission approved ciltacabtagene autoleucel for Multiple myeloma (Second-line therapy or greater) who have received prior proteasome inhibitor and immunomodulatory agent therapy, progressed on their last treatment, and are refractory to lenalidomide
- 06 Apr 2024 The US FDA approves Ciltacabtagene autoleucel for Multiple myeloma (Second-line therapy or greater) in USA